Key result
Protected LAA closure successfully prevents recurrent thromboembolism in a patient with mechanical valves and thrombus.
Why the study?
Antithrombotic management in patients with AF after heart valve surgery is challenging when thromboembolic events recur during follow-up, and combining pharmacological therapies with transcatheter interventions may help address these complex cases.
Can percutaneous left atrial appendage closure with cerebral embolic protection prevent recurrent thromboembolism in a patient with atrial fibrillation, mechanical heart valves, and a persistent left atrial appendage thrombus despite optimal vitamin K antagonist therapy?
Case Report (n=1)
No
Can percutaneous left atrial appendage closure with cerebral embolic protection prevent recurrent thromboembolism in a patient with atrial fibrillation, mechanical heart valves, and a persistent left atrial appendage thrombus despite optimal vitamin K antagonist therapy?
Answers are grounded in this paper and cite their sources.
Demonstrates that percutaneous left atrial appendage closure with cerebral embolic protection is a feasible adjunctive strategy to vitamin K antagonists in patients with mechanical heart valves, atrial fibrillation, persistent LAA thrombus, and recurrent cardioembolic events.
BACKGROUND: Antithrombotic management in patients with atrial fibrillation (AF) that have undergone heart valve surgery may be challenging, especially in the context of thromboembolic events during follow-up. The combination of pharmacological therapies with modern transcatheter interventions allows these more complex cases to be overcome. CASE SUMMARY: We present the case of a 66-year-old female with a history of AF and mechanical aortic and mitral valve replacement, which was admitted to the hospital complaining of dizziness and unsteady gait. A computerized tomography scan of the brain confirmed the diagnosis of embolic stroke. Two years later, the patient complained of sudden onset of chest pain, accompanied by electrocardiographic abnormalities and elevated high-sensitivity troponin T. Emergency cardiac catheterization revealed embolic myocardial infarction with distal occlusion of the obtuse marginal artery. Again, 2 years later, the patient suffered a new cerebral embolic event. Given the adequate anticoagulation therapy throughout almost the entire clinical course, percutaneous left atrial appendage closure was proposed as an adjunct to vitamin K antagonist treatment. Notably, intraprocedural transoesophageal echocardiography revealed the presence of a previously undetected left atrial appendage thrombus, thus an embolic protection device was used during the procedure, which was successfully carried out without complications. DISCUSSION: This case report demonstrates the complexity of the antithrombotic management in patients with AF and prosthetic heart valves, and highlights the importance of an individualized approach, integrating new therapeutic strategies to achieve success, in patients that present thromboembolic events despite adequate anticoagulation therapy.
No takes yet. Share an insight, caveat, or question.
Marschall et al. (2021) conducted a case report in Permanent atrial fibrillation and mechanical aortic and mitral heart valves with recurrent thromboembolic events despite adequate anticoagulation (n=1). Percutaneous left atrial appendage closure (Watchman FLX) supported by a cerebral protection system (SENTINEL) added to acenocoumarol was evaluated on Recurrent thromboembolic events and procedural complications. Percutaneous left atrial appendage closure with cerebral embolic protection was performed without complications and prevented further thromboembolic events in a patient with mechanical valves and LAA thrombus.
Synapse has enriched 10 related papers. Consider them for comparative context: